Golvatinib

Drug Profile

Golvatinib

Alternative Names: E-7050

Latest Information Update: 25 Sep 2015

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Piperazines; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Proto oncogene protein c met inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastric cancer; Glioblastoma; Head and neck cancer; Hepatocellular carcinoma; Malignant melanoma; Solid tumours

Most Recent Events

  • 15 Nov 2013 Eisai completes enrolment in its phase Ib/II trial for Head and neck cancer (second-line combination therapy, late-stage disease) in USA, United Kingdom, South Korea & Ukraine (NCT01332266)
  • 14 Nov 2013 Phase-I/II clinical trials in Hepatocellular carcinoma (first-line combination therapy, late-stage disease) in Italy & Ukraine (PO)
  • 01 Jul 2013 Eisai completes a phase I trial in Solid tumours in Japan (NCT01428141)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top